Abstract 314P
Background
Infectious agents account for 13-20% of new cancer cases worldwide and may have a role in the origin and progression of cancers and pathogenesis. Unfortunately, most commercially available genomic NGS assays neglect this increasingly important information. Herein, we describe next-generation sequencing (NGS) assays, OncoKey SL60 Plus and SL 525 Plus, that identifies DNA and RNA variants, as well as microbial signatures in various tumor types.
Methods
The automated hybridization capture-based NGS tests, OncoKey SL60 Plus and SL525 Plus, target 60 and 525, respectively, clinically relevant genes for small variants, MSI, splice variants, CNV and fusions, including 6 oncogenic viruses: EBV, HCV, HBV, MCPyV, KSHV and 30 subtypes of HPV, and 4 oncogenic bacteria: H. pylori, S. Typhi, S. gallolyticus and C. pneumoniae. Various commercial FFPE reference materials, cell lines harboring oncogenic viruses, and 32 FFPE clinical samples were characterized with the assays and sequenced on both the Illumina® MiSeq and NextSeq Systems.
Results
All expected DNA variants and RNA fusions in reference standards from as little as 40 ng of DNA/RNA input. In clinical samples, NGS results generally concurred with previous FISH/IHC and other molecular characterization thus demonstrating and equivalent accuracy. MCPyV and HBV were detected in MKL-1 and PLC/PRF/5 cell lines respectively, both of which are known carriers. Of the 32 FFPE samples, HPV16 and EBV were identified in 2 head and neck samples thus suggesting possible etiological roles. The presence of HPV and EBV was subsequently confirmed with IHC. In the EBV positive sample, BRCA2 p.G602fs mutation was also detected thus suggesting the patient may be a suitable candidate for PARP inhibitor therapies. In the HPV16 positive sample, PIK3CA p.R88Q was detected thus suggesting the patient may benefit from enroling into PIK3CA inhibitor trials.
Conclusions
Identifying virus and bacteria as etiological agents aids our understanding of the microbiome and cancer, diagnosis and treatment. NGS tools, such as the OncoKey SL60/525 Plus, provide rapid, high throughput and cost-effective strategies for comprehensive microbial and genomic profiling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vela Research Singapore.
Funding
Vela Research Singapore.
Disclosure
M.Q. Yee, Y.L. Kok, P. Ariyaratne, Y. Yu, O. Scully, D. Tay, C. Tang, T. Ong, H. Suhardi, K.K.M. Aye, A.W. Kyaw, E.Wee, C. Lee: Full/Part-time employment: Vela Research Singapore Pte. Ltd.
Resources from the same session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session